Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of latanoprost, dorzolamide, and timolol is an ophthalmic solution used to treat increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This triple combination leverages different mechanisms of action to effectively lower eye pressure. ## Composition and Mechanism This medication combines three active ingredients: - **Latanoprost** (0.05 mg/mL): A prostaglandin analog that increases the outflow of aqueous fluid from the eye through the uveoscleral pathway[7] - **Dorzolamide** (20 mg/mL): A carbonic anhydrase inhibitor that decreases the production of aqueous fluid in the eye[3][5] - **Timolol** (5 mg/mL): A non-selective beta blocker that blocks both beta-1 and beta-2 receptors in the eye, reducing aqueous fluid production[3][6] ## Clinical Effectiveness Studies have shown that this triple combination can be effective for patients whose eye pressure is not adequately controlled with monotherapy. The combination can provide significant IOP reduction, with one study showing a mean IOP decrease of 6.3 \u00b1 3.6 mm Hg (28.1%) when dorzolamide-timolol was added to existing latanoprost therapy[2]. ## Administration The medication is typically administered as eye drops, with one drop placed in the affected eye(s) twice daily[1][5]. Proper administration technique is important to maximize effectiveness and minimize systemic absorption. ## Side Effects Common side effects may include: - Eye irritation (12.0% of patients) - Taste perversion (4.3% of patients) - Blurry vision - Itchy eyes[2][6] Most adverse events are mild and non-serious. No serious adverse events related to this medication were reported in the studies reviewed[2]. ## Availability This combination is available as a prescription medication. It may be found as a branded product (TIM-DOR-LAT) or as a compounded medication[1]. Some versions are available in preservative-free formulations for patients who may be sensitive to preservatives[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on latanoprost + dorzolamide + timolol.